Amarin highlights ESC 2026 evidence supporting icosapent ethyl
AI Summary- Amarin highlighted ESC 2026 presentations on IPE, EPA and residual cardiovascular risk.
- 2026 ESC guidelines recognized REDUCE-IT RENAL evidence of reduced major cardiovascular events with IPE.
- Amarin said risk reductions were consistent across baseline eGFR subgroups, with larger absolute benefits at lower eGFR.